271 related articles for article (PubMed ID: 30050099)
1. Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S; Gieldon L; Pang Y; Peitzsch M; Huynh T; Leton R; Viana B; Ercolino T; Mangelis A; Rapizzi E; Menschikowski M; Aust D; Kroiss M; Beuschlein F; Gudziol V; Timmers HJ; Lenders J; Mannelli M; Cascon A; Pacak K; Robledo M; Eisenhofer G; Klink B
Genet Med; 2019 Mar; 21(3):705-717. PubMed ID: 30050099
[TBL] [Abstract][Full Text] [Related]
2. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
3. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.
Richter S; Garrett TJ; Bechmann N; Clifton-Bligh RJ; Ghayee HK
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36897220
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma.
Dwight T; Kim E; Novos T; Clifton-Bligh RJ
Horm Metab Res; 2019 Jul; 51(7):443-450. PubMed ID: 31307108
[TBL] [Abstract][Full Text] [Related]
8. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
9. Fumarate hydratase gene germline variants and mosaicism associated with pheochromocytoma and paraganglioma.
Ma X; Cui Y; Gao Y; Zhang X; Nie M; Tong A
Ann N Y Acad Sci; 2022 Oct; 1516(1):262-270. PubMed ID: 35821608
[TBL] [Abstract][Full Text] [Related]
10. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
11. Succinate detection using in vivo
Lussey-Lepoutre C; Bellucci A; Burnichon N; Amar L; Buffet A; Drossart T; Fontaine S; Clement O; Benit P; Rustin P; Groussin L; Meatchi T; Gimenez-Roqueplo AP; Tavitian B; Favier J
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1510-1517. PubMed ID: 31834447
[TBL] [Abstract][Full Text] [Related]
12. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
13. Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield.
Horton C; LaDuca H; Deckman A; Durda K; Jackson M; Richardson ME; Tian Y; Yussuf A; Jasperson K; Else T
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1917-e1923. PubMed ID: 35026032
[TBL] [Abstract][Full Text] [Related]
14. Germline FH mutations presenting with pheochromocytoma.
Clark GR; Sciacovelli M; Gaude E; Walsh DM; Kirby G; Simpson MA; Trembath RC; Berg JN; Woodward ER; Kinning E; Morrison PJ; Frezza C; Maher ER
J Clin Endocrinol Metab; 2014 Oct; 99(10):E2046-50. PubMed ID: 25004247
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Gaal J; Burnichon N; Korpershoek E; Roncelin I; Bertherat J; Plouin PF; de Krijger RR; Gimenez-Roqueplo AP; Dinjens WN
J Clin Endocrinol Metab; 2010 Mar; 95(3):1274-8. PubMed ID: 19915015
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.
Castro-Vega LJ; Buffet A; De Cubas AA; Cascón A; Menara M; Khalifa E; Amar L; Azriel S; Bourdeau I; Chabre O; Currás-Freixes M; Franco-Vidal V; Guillaud-Bataille M; Simian C; Morin A; Letón R; Gómez-Graña A; Pollard PJ; Rustin P; Robledo M; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2014 May; 23(9):2440-6. PubMed ID: 24334767
[TBL] [Abstract][Full Text] [Related]
17. Genetic and clinical aspects of paediatric pheochromocytomas and paragangliomas.
Petenuci J; Guimaraes AG; Fagundes GFC; Benedetti AFF; Afonso ACF; Pereira MAA; Zerbini MCN; Siqueira S; Yamauchi F; Soares SC; Srougi V; Tanno FY; Chambo JL; Lopes RI; Denes FT; Hoff AO; Latronico AC; Mendonca BB; Fragoso MCBV; Almeida MQ
Clin Endocrinol (Oxf); 2021 Jul; 95(1):117-124. PubMed ID: 33745191
[TBL] [Abstract][Full Text] [Related]
18. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
19. Genetic testing for pheochromocytoma and paraganglioma: SDHx carriers' experiences.
Martins RG; Carvalho IP
J Genet Couns; 2021 Jun; 30(3):872-884. PubMed ID: 33604970
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
